OPKO Health reports Q3 2026 results; completes sale of select BioReference assets to Labcorp for ~$722M

OPKO Health reported third-quarter 2026 financial results. The company announced a transaction with Labcorp selling select BioReference assets for approximately $722 million, marking a strategic shift toward focusing on biotech and global products.

Detected & updated continuously · Source: Nebula